Biotech Trial Calendar

107 companies · upcoming clinical trial readouts

Upcoming clinical-trial readout dates for mid- and large-cap biotech companies, plus the SEC filings where results get announced. Free to read, no account needed. Already have an account? Sign in for the live implied-volatility monitor and alerts.

Why implied volatility matters in biotech

A clinical trial is one of the few events in finance that is genuinely binary. The drug works or it doesn't, and the answer arrives on a single day. Biotech companies can lose most of their value, or multiply it, between one close and the next open — so the useful question is not only when a readout lands, but how large a move the market is braced for.

What it is

Implied volatility is the size of move that options traders are collectively paying to protect against. It is a forward-looking consensus, priced in real money, about how far a stock is likely to travel.

Why biotech is different

A large pharmaceutical company might sit near 30% implied volatility for years. A small biotech heading into a pivotal readout can run past 100%, sometimes far beyond — because the market knows one result is about to reprice the entire company.

What it's good for

It ranks the calendar. Dozens of trials complete every month, and volatility shows which ones traders think actually matter — often building before anything is announced publicly.

What it cannot tell you: direction. High volatility says a big move is expected, never which way. A trial that disappoints can erase most of a company's value just as quickly as a success can multiply it — that symmetry is precisely what the number is measuring. Treat it as a measure of how much is at stake, not as a prediction, and never as investment advice.

📅 Readout calendar 📄 Recent SEC 8-K filings
All readouts Next 90 days Phase 3 only High implied volatility Sort by IV
December 2026
AMGNAmgen Inc.
Phase 3ABP 234
Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
December 2026Ongoing
AXSMAxsome Therapeutics Inc.
Phase 3Solriamfetol 150 mg
Excessive Sleepiness; Shift-work Disorder
December 2026Recruiting
AXSMAxsome Therapeutics Inc.
Phase 3Solriamfetol 150 mg
Binge-Eating Disorder
December 2026Recruiting
BHVNBiohaven Ltd.
Phase 2BHV-7000
Focal Epilepsy
December 2026Enrolling
BHVNBiohaven Ltd.
Phase 2/3BHV-7000
Focal Epilepsy
December 2026Ongoing
BIIBBiogen Inc.
Phase 3Felzartamab
Antibody-mediated Rejection
December 2026Ongoing
DNLIDenali Therapeutics Inc.
Phase 1/2DNL593
Frontotemporal Dementia
December 2026Ongoing
DNTHDianthus Therapeutics Inc.
Phase 2Claseprubart
Multifocal Motor Neuropathy
December 2026Ongoing
EXELExelixis Inc.
Phase 3XL092
Non-Clear Cell Renal Cell Carcinoma
December 2026Ongoing
GILDGilead Sciences Inc.
Phase 3Sacituzumab Govitecan-hziy
Metastatic Breast Cancer
December 2026Ongoing
INCYIncyte Corporation
Phase 3Povorcitinib
Hidradenitis Suppurativa (HS)
December 2026Ongoing
INSMInsmed Incorporated
Phase 2/3Treprostinil Palmitil
Pulmonary Arterial Hypertension
December 2026Ongoing
IONSIonis Pharmaceuticals Inc.
Phase 3Donidalorsen
Hereditary Angioedema
December 2026Ongoing
JAZZJazz Pharmaceuticals plc
Phase 2Zanidatamab
Breast Cancer; Gastric Cancer
December 2026Recruiting
KRYSKrystal Biotech Inc.
Phase 3KB803
Dystrophic Epidermolysis Bullosa; DEB - Dystrophic Epidermolysis Bullosa
December 2026Recruiting
KRYSKrystal Biotech Inc.
Phase 1/2KB801
Neurotrophic Keratitis
December 2026Recruiting
MANEVeradermics Incorporated
Phase 3VDPHL01
Androgenetic Alopecia; AGA
December 2026Ongoing
MDGLMadrigal Pharmaceuticals Inc.
Phase 3Resmetirom
NASH; Cirrhosis, Liver
December 2026Ongoing
PRAXPraxis Precision Medicines Inc.
Phase 31mg elsunersen
Epileptic Encephalopathy; SCN2A Encephalopathy
December 2026Recruiting
PRAXPraxis Precision Medicines Inc.
Phase 31.0mg/kg/day PRAX-562
Developmental and Epileptic Encephalopathy 1
December 2026Ongoing
REGNRegeneron Pharmaceuticals Inc.
Phase 2REGN7999
Non-Transfusion Dependent Beta-Thalassemia (NTDT)
December 2026Ongoing
REGNRegeneron Pharmaceuticals Inc.
Phase 2Alirocumab
Hypercholesterolemia
December 2026Ongoing
SLSSELLAS Life Sciences Group Inc.
Phase 1/2SLS009
Hematologic Malignancies
December 2026Recruiting
SUPNSupernus Pharmaceuticals Inc.
Phase 1/2BIS-001ER
Focal Impaired Awareness Seizures
December 2026Ongoing
SUPNSupernus Pharmaceuticals Inc.
Phase 2SPN-821 2400 mg
Major Depressive Disorder (MDD)
December 2026Recruiting
TARSTarsus Pharmaceuticals Inc.
Phase 2lotilaner
Ocular Rosacea
December 2026Enrolling
UTHRUnited Therapeutics Corporation
Phase 3Ralinepag
PAH; Pulmonary Hypertension
December 2026Enrolling
January 2027
AMGNAmgen Inc.
Phase 1/2AMG 732
Thyroid Eye Disease
January 2027Ongoing
AMGNAmgen Inc.
Phase 3Maridebart Cafraglutide
Obesity
January 2027Ongoing
AMGNAmgen Inc.
Phase 3Maridebart cafraglutide
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
January 2027Ongoing
EWTXEdgewise Therapeutics Inc.
Phase 2Sevasemten Dose 1
Duchenne Muscular Dystrophy
January 2027Ongoing
GILDGilead Sciences Inc.
Phase 2Tilpisertib Fosmecarbil
Ulcerative Colitis
January 2027Ongoing
IDYAIDEAYA Biosciences Inc.
Phase 2/3IDE196
Metastatic Uveal Melanoma
January 2027Ongoing
IDYAIDEAYA Biosciences Inc.
Phase 1/2IDE196
Metastatic Uveal Melanoma; Cutaneous Melanoma
January 2027Recruiting
INCYIncyte Corporation
Phase 1/2INCA034176
Chronic Graft-versus-host-disease
January 2027Ongoing
MIRMMirum Pharmaceuticals Inc.
Phase 2Volixibat
Primary Biliary Cholangitis; PBC
January 2027Ongoing
MRNAModerna Inc.
Phase 3mRNA-1018-H5
Influenza
January 2027Ongoing
PRAXPraxis Precision Medicines Inc.
Phase 340 mg/day vormatrogine for 12 weeks
Focal Epilepsy
January 2027Ongoing
RAREUltragenyx Pharmaceutical Inc.
Phase 3setrusumab
Osteogenesis Imperfecta
January 2027Ongoing
REGNRegeneron Pharmaceuticals Inc.
Phase 3Fianlimab
Melanoma
January 2027Ongoing
TGTXTG Therapeutics Inc.
Phase 3Ublituximab
Relapsing Multiple Sclerosis
January 2027Recruiting
TLXTelix Pharmaceuticals Limited
Phase 368Ga-PSMA-11
PCA; Prostate Cancer
January 2027Ongoing
VRTXVertex Pharmaceuticals Inc.
Phase 3Suzetrigine
Diabetic Peripheral Neuropathic Pain
January 2027Ongoing
XENEXenon Pharmaceuticals Inc.
Phase 3Azetukalner
Major Depressive Disorder
January 2027Ongoing
February 2027
GILDGilead Sciences Inc.
Phase 3Sacituzumab Govitecan-hziy
Triple Negative Breast Cancer; PD-L1 Positive
February 2027Ongoing
KODKodiak Sciences Inc
Phase 3KSI-101
Macular Edema Secondary to Inflammation
February 2027Recruiting
KRYSKrystal Biotech Inc.
Phase 1/2KB707
Lung Cancer, Non-small Cell; Lung Cancer Metastatic
February 2027Recruiting
LQDALiquidia Corporation
Phase 2LIQ861 (treprostinil) inhalation powder
Raynaud's Phenomenon Secondary to Systemic Sclerosis
February 2027Not Yet Recruiting
MRNAModerna Inc.
Phase 3mRNA-1403
Acute Gastroenteritis; Norovirus Acute Gastroenteritis
February 2027Ongoing
NBIXNeurocrine Biosciences Inc.
Phase 2NBI-1065890
Tardive Dyskinesia
February 2027Recruiting
REGNRegeneron Pharmaceuticals Inc.
Phase 2REGN7508
Atrial Fibrillation (AF)
February 2027Recruiting
REGNRegeneron Pharmaceuticals Inc.
Phase 3REGN7508
Venous Thromboembolism (VTE)
February 2027Recruiting
VRTXVertex Pharmaceuticals Inc.
Phase 1/2VX-670
Myotonic Dystrophy Type 1 (DM1)
February 2027Ongoing
March 2027
ARGXargenx SE
Phase 2/3Efgartigimod IV
Generalized Myasthenia Gravis
March 2027Ongoing
ARGXargenx SE
Phase 2Efgartigimod PH20 SC
Systemic Sclerosis (SSc)
March 2027Ongoing
CGONCG Oncology, Inc.
Phase 2Cretostimogene Grenadenorepvec
High-Risk Non-Muscle-Invasive Bladder Cancer
March 2027Recruiting
DNLIDenali Therapeutics Inc.
Phase 2BIIB122 225 mg
Parkinson Disease
March 2027Ongoing
EWTXEdgewise Therapeutics Inc.
Phase 2Sevasemten Dose 1
Duchenne Muscular Dystrophy
March 2027Ongoing
GILDGilead Sciences Inc.
Phase 2Oral Lenacapavir
HIV-1-infection
March 2027Recruiting
GILDGilead Sciences Inc.
Phase 2Sacituzumab Govitecan-hziy (SG)
Non-small Cell Lung Cancer
March 2027Ongoing
GILDGilead Sciences Inc.
Phase 2Domvanalimab
Head and Neck Squamous Cell Carcinoma
March 2027Ongoing
IBRXImmunityBio Inc.
Phase 2Anktiva
Long COVID; Long COVID Syndrome
March 2027Recruiting
IONSIonis Pharmaceuticals Inc.
Phase 3Olezarsen
Severe Hypertriglyceridemia
March 2027Ongoing
KYKOFKyowa Kirin Co. Ltd.
Phase 2ziftomenib
Acute Myeloid Leukemia (AML)
March 2027Recruiting
MDGLMadrigal Pharmaceuticals Inc.
Phase 3Resmetirom
Non-Alcoholic Fatty Liver Disease
March 2027Ongoing
MRNAModerna Inc.
Phase 2mRNA-1647
Cytomegalovirus Infection
March 2027Ongoing
RYTMRhythm Pharmaceuticals Inc.
Phase 3Setmelanotide
Hypothalamic Obesity; Multiple Pituitary Hormone Deficiency Genetic Form
March 2027Recruiting
TVTXTravere Therapeutics Inc.
Phase 2Sparsentan
Focal Segmental Glomerulosclerosis; Minimal Change Disease
March 2027Recruiting
VRTXVertex Pharmaceuticals Inc.
Phase 1/2VX-264
Type 1 Diabetes
March 2027Ongoing
VRTXVertex Pharmaceuticals Inc.
Phase 2VX-993
Diabetic Peripheral Neuropathic Pain
March 2027Recruiting
ZLABZai Lab Limited
Phase 3ZL-1109 (VRDN-003)
Thyroid Eye Disease (TED)
March 2027Ongoing
April 2027
ALNYAlnylam Pharmaceuticals Inc.
Phase 1/2ALN-2232
Obesity
April 2027Recruiting
AMGNAmgen Inc.
Phase 2Inebilizumab
Neuromyelitis Optica Spectrum Disorder
April 2027Recruiting
AMGNAmgen Inc.
Phase 3Ocrelizumab (US)
Relapsing-remitting Multiple Sclerosis (RRMS)
April 2027Ongoing
AMGNAmgen Inc.
Phase 3Maridebart cafraglutide
Obesity Disease
April 2027Ongoing
ARGXargenx SE
Phase 2Efgartigimod PH20 SC
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
April 2027Ongoing
BMRNBioMarin Pharmaceutical Inc.
Phase 1/2BMN 351
Duchenne Muscular Dystrophy
April 2027Ongoing
BNTXBioNTech SE
Phase 3BNT162b2
COVID-19 Vaccines
April 2027Recruiting
GKOSGlaukos Corporation
Phase 2GLK-221 Ophthalmic Solution
Keratoconus
April 2027Recruiting
HRMYHarmony Biosciences Holdings Inc.
Phase 3Pitolisant tablet
Prader-Willi Syndrome
April 2027Recruiting
IDYAIDEAYA Biosciences Inc.
Phase 2Darovasertib
Uveal Melanoma
April 2027Ongoing
INCYIncyte Corporation
Phase 2INCB123667
Ovarian Cancer
April 2027Recruiting
INCYIncyte Corporation
Phase 3Ruxolitinib Cream
NonSegmental Vitiligo
April 2027Recruiting
IONSIonis Pharmaceuticals Inc.
Phase 1/2ION717
Prion Disease
April 2027Ongoing
KODKodiak Sciences Inc
Phase 3KSI-101
Macular Edema Secondary to Inflammation
April 2027Recruiting
KYKOFKyowa Kirin Co. Ltd.
Phase 1/2KK2430
Hematologic Neoplasms
April 2027Recruiting
LGNDLigand Pharmaceuticals Incorporated
Phase 3Lasofoxifene + abemaciclib
ER+/HER2- breast cancer with an ESR1 mutation
April 2027Enrollment Initiation
VRTXVertex Pharmaceuticals Inc.
Phase 3ELX/TEZ/IVA
Cystic Fibrosis
April 2027Ongoing
VRTXVertex Pharmaceuticals Inc.
Phase 3Suzetrigine
Diabetic Peripheral Neuropathic Pain
April 2027Recruiting
XENEXenon Pharmaceuticals Inc.
Phase 3XEN1101
Primary Generalized Tonic-Clonic Seizures
April 2027Recruiting
May 2027
ALNYAlnylam Pharmaceuticals Inc.
Phase 2ALN-4324
Type 2 Diabetes Mellitus (T2DM)
May 2027Ongoing
BIIBBiogen Inc.
Phase 3BIIB017 (peginterferon beta-1a)
Multiple Sclerosis, Relapsing-Remitting
May 2027Ongoing
BIIBBiogen Inc.
Phase 3Felzartamab
Immunoglobulin A Nephropathy (IgAN)
May 2027Recruiting
CRNXCrinetics Pharmaceuticals Inc.
Phase 3Atumelnant
Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasia
May 2027Recruiting
GILDGilead Sciences Inc.
Phase 1/2Sacituzumab Govitecan-hziy
Advanced Solid Tumor; Metastatic Triple-Negative Breast Cancer
May 2027Ongoing
IBRXImmunityBio Inc.
Phase 2Gemcitabine
Platinum-resistant Ovarian Cancer
May 2027Recruiting
IBRXImmunityBio Inc.
Phase 2CD19 t-haNK- IV Administration
Relapsed B-Cell Non Hodgkin Lymphoma
May 2027Recruiting
IMVTImmunovant Inc.
Phase 2IMVT-1402
Graves' Disease
May 2027Recruiting
IRONDisc Medicine Inc.
Phase 1/2DISC-0974
Myelofibrosis; Anemia; Anemia
May 2027Recruiting
KLRAKailera Therapeutics Inc.
Phase 2Ribupatide
Obesity
May 2027Ongoing
RYTMRhythm Pharmaceuticals Inc.
Phase 1/2Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)
Hypothalamic Obesity; Prader-Willi Syndrome
May 2027Ongoing
VRTXVertex Pharmaceuticals Inc.
Phase 3Suzetrigine
Diabetic Peripheral Neuropathic Pain
May 2027Recruiting
XENEXenon Pharmaceuticals Inc.
Phase 3Azetukalner
Major Depressive Disorder
May 2027Ongoing
June 2027
ALNYAlnylam Pharmaceuticals Inc.
Phase 2ALN-6400
Von Willebrand Disease (VWD); Heavy Menstrual Bleeding (HMB)
June 2027Recruiting
BLTEBelite Bio Inc
Phase 3Tinlarebant
Geographic Atrophy
June 2027Ongoing
BNTXBioNTech SE
Phase 2BNT327 Dose Level 1 (DL1)
Extensive-stage Small-cell Lung Cancer; Small-cell Lung Cancer
June 2027Ongoing
BNTXBioNTech SE
Phase 2BNT166a
Mpox (Monkeypox); Smallpox
June 2027Recruiting
DNLIDenali Therapeutics Inc.
Phase 2/3tividenofusp alfa
Mucopolysaccharidosis II
June 2027Enrolling
GILDGilead Sciences Inc.
Phase 3Sacituzumab govitecan-hziy (SG)
Triple Negative Breast Cancer
June 2027Recruiting
IONSIonis Pharmaceuticals Inc.
Phase 3Olezarsen
Familial Chylomicronemia Syndrome
June 2027Ongoing
KYMRKymera Therapeutics Inc.
Phase 2KT-621
Atopic Dermatitis
June 2027Ongoing
MANEVeradermics Incorporated
Phase 3VDPHL01 QD
Androgenetic Alopecia (AGA); Androgenetic Alopecia
June 2027Ongoing
MIRMMirum Pharmaceuticals Inc.
Phase 3Brelovitug 300 mg
Chronic Hepatitis D Infection
June 2027Recruiting
PHVSPharvaris N.V.
Phase 3Deucrictibant
Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
June 2027Recruiting
PHVSPharvaris N.V.
Phase 2/3deucrictibant
Hereditary Angioedema; Hereditary Angioedema Type I
June 2027Enrolling
SYRESpyre Therapeutics Inc.
Phase 2SPY001
Ulcerative Colitis; Inflammatory Bowel Diseases
June 2027Recruiting
VRTXVertex Pharmaceuticals Inc.
Phase 3CTX001
Sickle Cell Disease; Hydroxyurea Failure
June 2027Ongoing
July 2027
ARGXargenx SE
Phase 3Efgartigimod PH20 SC
Primary Sjogrens Disease
July 2027Ongoing
COAGHemab Therapeutics Holdings Inc.
Phase 1/2HMB-002 (Part A)
Von Willebrand Disease (VWD); Von Willebrand Disease (VWD), Type 1
July 2027Recruiting
INCYIncyte Corporation
Phase 2INCB000928
Fibrodysplasia Ossificans Progressiva (FOP)
July 2027Recruiting
IRONDisc Medicine Inc.
Phase 2DISC-3405
Polycythemia Vera (PV)
July 2027Ongoing
KLRAKailera Therapeutics Inc.
Phase 2KAI-7535
Obesity; Overweight
July 2027Ongoing
KRYSKrystal Biotech Inc.
Phase 1/2KB707
Cancer; Melanoma Stage III
July 2027Recruiting
NBIXNeurocrine Biosciences Inc.
Phase 3NBI-1065845
Major Depressive Disorder
July 2027Recruiting
NBIXNeurocrine Biosciences Inc.
Phase 3NBI-1065845
Major Depressive Disorder
July 2027Recruiting
NBIXNeurocrine Biosciences Inc.
Phase 3NBI-1065845
Major Depressive Disorder
July 2027Recruiting
TGTXTG Therapeutics Inc.
Phase 2Ublituximab
Multiple Sclerosis
July 2027Recruiting
TVTXTravere Therapeutics Inc.
Phase 1/2Pegtibatinase
Homocystinuria
July 2027Recruiting
VKTXViking Therapeutics Inc.
Phase 3VK2735
Weight Loss
July 2027Ongoing
VKTXViking Therapeutics Inc.
Phase 3VK2735
Weight Loss
July 2027Ongoing
August 2027
ACADACADIA Pharmaceuticals Inc.
Phase 2ACP-211
Major Depressive Disorder (MDD); Depressive Disorder, Treatment-Resistant
August 2027Recruiting
ALNYAlnylam Pharmaceuticals Inc.
Phase 2ALN-APP
Cerebral Amyloid Angiopathy
August 2027Ongoing
ALNYAlnylam Pharmaceuticals Inc.
Phase 1/2ALN-4324
Obese or Overweight Healthy Volunteers; Type 2 Diabetes Mellitus (T2DM)
August 2027Ongoing
BHVNBiohaven Ltd.
Phase 2/3BHV-8000 10mg
Parkinson Disease
August 2027Recruiting
BIIBBiogen Inc.
Phase 3Tofersen
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
August 2027Ongoing
COAGHemab Therapeutics Holdings Inc.
Phase 1/2HMB-001
Glanzmann Thrombasthenia
August 2027Ongoing
CRNXCrinetics Pharmaceuticals Inc.
Phase 3Paltusotine
Carcinoid Syndrome; Carcinoid
August 2027Ongoing
CRNXCrinetics Pharmaceuticals Inc.
Phase 1/2CRN09682
SST2-positive Neuroendocrine Neoplasms; Neuroendocrine Tumors
August 2027Ongoing
IBRXImmunityBio Inc.
Phase 2Nogapendekin alfa inbakicept (NAI)
Sepsis; Septic Shock
August 2027Not Yet Recruiting
INCYIncyte Corporation
Phase 2Tafasitamab
Hematologic Malignancies
August 2027Recruiting
IONSIonis Pharmaceuticals Inc.
Phase 3obudanersen
Angelman Syndrome
August 2027Ongoing
LNTHLantheus Holdings Inc.
Phase 1/2LNTH2403 Phase 1 dose
Relapsed / Refractory Osteosarcoma
August 2027Recruiting
MIRMMirum Pharmaceuticals Inc.
Phase 2/3Brelovitug (BJT-778)
Chronic Hepatitis D
August 2027Recruiting
MRNAModerna Inc.
Phase 1/2mRNA-3927
Propionic Acidemia
August 2027Recruiting
NBIXNeurocrine Biosciences Inc.
Phase 2NBI-1117570
Schizophrenia
August 2027Recruiting
RAREUltragenyx Pharmaceutical Inc.
Phase 3No Investigational Product
Mucopolysaccharidosis IIIA; MPS IIIA
August 2027Enrolling
RAREUltragenyx Pharmaceutical Inc.
Phase 3Triheptanoin
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
August 2027Ongoing
SUPNSupernus Pharmaceuticals Inc.
Phase 2SPN-817
Focal Onset Seizures
August 2027Recruiting
TLXTelix Pharmaceuticals Limited
Phase 3177Lu-TLX250
ccRCC; Renal Cell Carcinoma (Kidney Cancer)
August 2027Recruiting
TRVITrevi Therapeutics Inc.
Phase 3NAL ER
Idiopathic Pulmonary Fibrosis
August 2027Recruiting
TVTXTravere Therapeutics Inc.
Phase 3Pegtibatinase
Homocystinuria
August 2027Recruiting
ZLABZai Lab Limited
Phase 1/2ZL-1310
Solid Tumors
August 2027Recruiting
September 2027
ARGXargenx SE
Phase 2/3Efgartigimod PH20 SC
Generalized Myasthenia Gravis
September 2027Recruiting
ARGXargenx SE
Phase 3empasiprubart
Chronic Inflammatory Demyelinating Polyneuropathy; CIDP
September 2027Recruiting
BIIBBiogen Inc.
Phase 3Nusinersen
Spinal Muscular Atrophy
September 2027Ongoing
DFTXDefinium Therapeutics Inc.
Phase 3DT120
Major Depressive Disorder
September 2027Recruiting
GRFSGrifols S.A.
Phase 3Alpha-1 15%
Alpha 1 Antitrypsin Deficiency
September 2027Recruiting
IMVTImmunovant Inc.
Phase 2IMVT-1402
Rheumatoid Arthritis
September 2027Ongoing
IONSIonis Pharmaceuticals Inc.
Phase 2ION775
Hypertriglyceridemia; Severe Hypertriglyceridemia
September 2027Recruiting
IONSIonis Pharmaceuticals Inc.
Phase 1/2ION440
Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
September 2027Recruiting
PTCTPTC Therapeutics Inc.
Phase 2PTC844
Rheumatoid Arthritis
September 2027Recruiting
RAREUltragenyx Pharmaceutical Inc.
Phase 3DTX301
OTC Deficiency
September 2027Ongoing
TRVITrevi Therapeutics Inc.
Phase 2NAL ER
Refractory Chronic Cough
September 2027Recruiting
October 2027
ARGXargenx SE
Phase 2Empasiprubart IV
AChR-Ab Seropositive Generalized Myasthenia Gravis; Myasthenia Gravis (MG)
October 2027Recruiting
HRMYHarmony Biosciences Holdings Inc.
Phase 3HBS-301 tablet
Idiopathic Hypersomnia
October 2027Recruiting
HRMYHarmony Biosciences Holdings Inc.
Phase 3HBS-301
EDS; Cataplexy
October 2027Recruiting
MIRMMirum Pharmaceuticals Inc.
Phase 2Low dose of MRM-3379
Fragile X Syndrome
October 2027Recruiting
NBIXNeurocrine Biosciences Inc.
Phase 3NBI-1117568
Schizophrenia
October 2027Recruiting
ORKAOruka Therapeutics Inc.
Phase 2ORKA-002
Plaque Psoriasis
October 2027Ongoing
SYRESpyre Therapeutics Inc.
Phase 2SPY072
Hidradenitis Suppurativa (HS)
October 2027Recruiting
TARSTarsus Pharmaceuticals Inc.
Phase 2TP-05 (lotilaner) Low Dose
Lyme Disease
October 2027Ongoing
November 2027
BIIBBiogen Inc.
Phase 3Omaveloxolone
Friedreich Ataxia
November 2027Ongoing
BNTXBioNTech SE
Phase 1/2BNT3212
Advanced Solid Tumor
November 2027Recruiting
COAGHemab Therapeutics Holdings Inc.
Phase 2Sutacimig
Congenital Factor VII Deficiency
November 2027Recruiting
NAMSNewAmsterdam Pharma Company N.V.
Phase 3obicetrapib 10 mg + ezetimibe 10 mg FDC daily
Lipidemia; Coronary Artery Disease
November 2027Ongoing
NBIXNeurocrine Biosciences Inc.
Phase 3NBI-1117568
Schizophrenia
November 2027Recruiting
UTHRUnited Therapeutics Corporation
Phase 3Inhaled Treprostinil
Progressive Pulmonary Fibrosis; Interstitial Lung Disease
November 2027Recruiting
VERAVera Therapeutics Inc.
Phase 2Atacicept
pMN; IgAN
November 2027Recruiting
December 2027
ALMSAlumis Inc.
Phase 2envudeucitinib
Plaque Psoriasis
December 2027Ongoing
ALNYAlnylam Pharmaceuticals Inc.
Phase 3Nucresiran
Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; hATTR-PN
December 2027Recruiting
AXSMAxsome Therapeutics Inc.
Phase 3AXS-05 (dextromethorphan-bupropion)
Smoking Cessation
December 2027Recruiting
AXSMAxsome Therapeutics Inc.
Phase 3Solriamfetol
Binge-Eating Disorder
December 2027Enrolling
AXSMAxsome Therapeutics Inc.
Phase 3Solriamfetol
ADHD
December 2027Enrolling
BMRNBioMarin Pharmaceutical Inc.
Phase 1/2BMN 307
Phenylketonuria (PKU)
December 2027Ongoing
BMRNBioMarin Pharmaceutical Inc.
Phase 2BMN 111
Achondroplasia
December 2027Ongoing
BMRNBioMarin Pharmaceutical Inc.
Phase 2vosoritide
Achondroplasia
December 2027Ongoing
BNTXBioNTech SE
Phase 2Pumitamig
Pancreatic Ductal Adenocarcinoma (PDAC)
December 2027Recruiting
DNLIDenali Therapeutics Inc.
Phase 2/3tividenofusp alfa
Mucopolysaccharidosis II
December 2027Ongoing
EWTXEdgewise Therapeutics Inc.
Phase 2EDG-15400 25 mg
Heart Failure With Preserved Ejection Fraction
December 2027Recruiting
EWTXEdgewise Therapeutics Inc.
Phase 2EDG-7500
Hypertrophic Cardiomyopathy
December 2027Ongoing
GRFSGrifols S.A.
Phase 3Gamunex-C
CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
December 2027Recruiting
IBRXImmunityBio Inc.
Phase 2CD19 t-haNK- IV Administration
Relapsed B-Cell Non-Hodgkin Lymphoma
December 2027Not Yet Recruiting
IMVTImmunovant Inc.
Phase 3IMVT-1402
Generalized Myasthenia Gravis
December 2027Recruiting
JAZZJazz Pharmaceuticals plc
Phase 3Xywav
Narcolepsy; Idiopathic Hypersomnia
December 2027Recruiting
JAZZJazz Pharmaceuticals plc
Phase 2Zanidatamab
HER2-positive Breast Cancer; Breast Cancer
December 2027Recruiting
KNSAKiniksa Pharmaceuticals International plc
Phase 2/3KPL-387
Pericarditis; Pericarditis Acute
December 2027Recruiting
KNSAKiniksa Pharmaceuticals International plc
Phase 2KPL-387
Recurrent Pericarditis; Heart Diseases
December 2027Recruiting
KYMRKymera Therapeutics Inc.
Phase 2KT-621
Eosinophilic Asthma
December 2027Recruiting
PCVXVaxcyte Inc.
Phase 20.5 mL of the low dose VAX-31
Pneumococcal Vaccines
December 2027Ongoing
PTCTPTC Therapeutics Inc.
Phase 3Vatiquinone
Friedreich Ataxia
December 2027Ongoing
SUPNSupernus Pharmaceuticals Inc.
Phase 2SPN-817
Epilepsy; Seizures, Epileptic
December 2027Recruiting
SUPNSupernus Pharmaceuticals Inc.
Phase 2SPN-817
Focal Onset Seizures
December 2027Enrolling
TLXTelix Pharmaceuticals Limited
Phase 3177Lu-TLX591
Metastatic Castration-resistant Prostate Cancer
December 2027Recruiting
January 2028
ACADACADIA Pharmaceuticals Inc.
Phase 2/3ACP-204
Alzheimer's Disease Psychosis
January 2028Recruiting
ALNYAlnylam Pharmaceuticals Inc.
Phase 1/2ALN-6400
Hereditary Hemorrhagic Telangiectasia
January 2028Ongoing
BHVNBiohaven Ltd.
Phase 3BHV-1300
Graves Disease
January 2028Recruiting
BIIBBiogen Inc.
Phase 2Felzartamab
Graves' Disease
January 2028Recruiting
BNTXBioNTech SE
Phase 2Pumitamig
Recurrent Glioblastoma
January 2028Recruiting
CELCCelcuity Inc.
Phase 1/2Gedatolisib
mCRPC (Metastatic Castration-resistant Prostate Cancer); Genital Diseases, Male
January 2028Recruiting
JAZZJazz Pharmaceuticals plc
Phase 1/2Lurbinectedin
Refractory Ewing Sarcoma; Relapsed Ewing Sarcoma
January 2028Recruiting
MBXMBX Biosciences Inc.
Phase 3Canvuparatide
Hypoparathyroidism
January 2028Recruiting
MDGLMadrigal Pharmaceuticals Inc.
Phase 3MGL-3196
NASH - Nonalcoholic Steatohepatitis
January 2028Ongoing
NRIXNurix Therapeutics Inc.
Phase 2NX-5948
Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
January 2028Recruiting
XENEXenon Pharmaceuticals Inc.
Phase 3XEN1101
Focal Onset Seizures
January 2028Recruiting
February 2028
ACADACADIA Pharmaceuticals Inc.
Phase 2ACP-204
Lewy Body Dementia Psychosis
February 2028Recruiting
BHVNBiohaven Ltd.
Phase 1/2BHV-1510
Solid Tumor
February 2028Recruiting
BIIBBiogen Inc.
Phase 2Felzartamab
Microvascular Inflammation
February 2028Recruiting
BLTEBelite Bio Inc
Phase 2/3Tinlarebant
STGD1; Stargardt Disease 1
February 2028Ongoing
EXELExelixis Inc.
Phase 2Zanzalintinib
Meningioma
February 2028Recruiting
IBRXImmunityBio Inc.
Phase 1/2Intravesical Recombinant Mycobacterium (rMBCG)
NMIBC
February 2028Recruiting
IONSIonis Pharmaceuticals Inc.
Phase 3Olezarsen
Familial Chylomicronemia Syndrome
February 2028Ongoing
KLRAKailera Therapeutics Inc.
Phase 3Ribupatide
Obesity; Overweight
February 2028Ongoing
NBIXNeurocrine Biosciences Inc.
Phase 2NBI-1117568
Bipolar I Disorder; Mania
February 2028Recruiting
March 2028
ALNYAlnylam Pharmaceuticals Inc.
Phase 3Vutrisiran
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
March 2028Enrolling
AXSMAxsome Therapeutics Inc.
Phase 3AXS-14 (Esreboxetine)
Fibromyalgia
March 2028Recruiting
BNTXBioNTech SE
Phase 1/2BNT326
Advanced Solid Tumor
March 2028Recruiting
GKOSGlaukos Corporation
Phase 2Gen 2 Travoprost Intracameral Implant
Glaucoma
March 2028Recruiting
HALOHalozyme Therapeutics Inc.
Phase 3Testosterone enanthate
Hypogonadism, Male
March 2028Recruiting
KLRAKailera Therapeutics Inc.
Phase 3Ribupatide
Obesity
March 2028Ongoing
KLRAKailera Therapeutics Inc.
Phase 3Ribupatide
Obesity With Diabetes; Overweight With Diabetes
March 2028Ongoing
LNTHLantheus Holdings Inc.
Phase 3[18F]PI-2620
Alzheimer Disease
March 2028Recruiting
NAMSNewAmsterdam Pharma Company N.V.
Phase 3obicetrapib 10 mg + ezetimibe 10 mg FDC daily
Lipidemia; Type 2 Diabetes (T2DM)
March 2028Ongoing
April 2028
ARQTArcutis Biotherapeutics Inc.
Phase 3Roflumilast Cream 0.3%
Atopic Dermatitis; Atopic Dermatitis (AD)
April 2028Recruiting
ERASErasca Inc.
Phase 3Naporafenib
Advanced or Metastatic NRAS-mutant Melanoma
April 2028Ongoing
JAZZJazz Pharmaceuticals plc
Phase 3Zanidatamab
Metastatic HER2-positive Breast Cancer
April 2028Recruiting
RCUSArcus Biosciences Inc.
Phase 3Casdatifan
Metastatic Clear Cell Renal Cell Carcinoma; Advanced Clear Cell Renal Cell Carcinoma
April 2028Recruiting
RLAYRelay Therapeutics Inc.
Phase 3Zovegalisib
PIK3CA Mutation; HER2- Negative Breast Cancer
April 2028Recruiting
RYTMRhythm Pharmaceuticals Inc.
Phase 2Bivamelagon
Hypothalamic Obesity
April 2028Enrolling
TLXTelix Pharmaceuticals Limited
Phase 3Floretyrosine F 18 ([18F]FET)
Brain Metastasis; Radiation Necrosis
April 2028Not Yet Recruiting
May 2028
AXSMAxsome Therapeutics Inc.
Phase 3AXS-14 (esreboxetine)
Fibromyalgia
May 2028Enrolling
IBRXImmunityBio Inc.
Phase 2Nogapendekin alfa inbakicept (NAI)
Sepsis
May 2028Not Yet Recruiting
IONSIonis Pharmaceuticals Inc.
Phase 3obudanersen
Angelman Syndrome
May 2028Recruiting
KYKOFKyowa Kirin Co. Ltd.
Phase 2ME-401
Indolent B-cell Non-Hodgkin's Lymphoma
May 2028Ongoing
MBXMBX Biosciences Inc.
Phase 2400 µg of MBX 2109 once-weekly by subcutaneous injection
Hypoparathyroidism
May 2028Ongoing
NKTRNektar Therapeutics
Phase 3Rezpegaldesleukin
Moderate-to-Severe Atopic Dermatitis
May 2028Recruiting
PRAXPraxis Precision Medicines Inc.
Phase 3vormatrogine
Epilepsy, Tonic-Clonic; Focal Seizure
May 2028Enrolling
UTHRUnited Therapeutics Corporation
Phase 2treprostinil SMI (treprostinil inhalation spray)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
May 2028Not Yet Recruiting
June 2028
AXSMAxsome Therapeutics Inc.
Phase 3Solriamfetol Dose A
ADHD
June 2028Recruiting
BMRNBioMarin Pharmaceutical Inc.
Phase 2Vosoritide
Hypochondroplasia
June 2028Recruiting
CLDXCelldex Therapeutics Inc.
Phase 3Barzolvolimab
Chronic Inducible Urticaria; Cold Urticaria
June 2028Recruiting
EXELExelixis Inc.
Phase 2Carboplatin
Squamous Non-Small Cell Lung Cancer (NSCLC)
June 2028Recruiting
GKOSGlaukos Corporation
Phase 3Gen 2 Travoprost Intracameral Implant
Glaucoma
June 2028Recruiting
IMVTImmunovant Inc.
Phase 2IMVT-1402
Graves' Disease
June 2028Recruiting
IRONDisc Medicine Inc.
Phase 2/3DISC-1459
Erythropoietic Protoporphyria
June 2028Enrolling
JAZZJazz Pharmaceuticals plc
Phase 3Dordaviprone (ONC201)
H3 K27M; Glioma
June 2028Recruiting
NKTRNektar Therapeutics
Phase 3Rezpegaldesleukin
Moderate-to-Severe Atopic Dermatitis
June 2028Recruiting
TRVITrevi Therapeutics Inc.
Phase 3NAL ER
Idiopathic Pulmonary Fibrosis
June 2028Recruiting
XENEXenon Pharmaceuticals Inc.
Phase 3Azetukalner
Bipolar Disorder; Bipolar Depression
June 2028Ongoing
ZLABZai Lab Limited
Phase 3ZL-1310
Small-cell Lung Cancer
June 2028Recruiting
July 2028
CRSPCRISPR Therapeutics AG
Phase 1/2CTX340
Hypertension
July 2028Recruiting
DYNDyne Therapeutics Inc.
Phase 3zeleciment basivarsen (DYNE-101)
Myotonic Dystrophy Type 1 (DM1); DM1
July 2028Recruiting
IMVTImmunovant Inc.
Phase 2IMVT-1402
Primary Sjögren's Syndrome
July 2028Ongoing
TARSTarsus Pharmaceuticals Inc.
Phase 2TP-06
Persistent Corneal Epithelial Defect
July 2028Recruiting
TGTXTG Therapeutics Inc.
Phase 2Ublituximab
Myasthenia Gravis
July 2028Recruiting
TLXTelix Pharmaceuticals Limited
Phase 3TLX-101-Tx + Lomustine
Neoplastic Disease; Glioblastoma
July 2028Recruiting
VKTXViking Therapeutics Inc.
Phase 3VK2735
Weight Loss
July 2028Recruiting
August 2028
EXELExelixis Inc.
Phase 2/3Zanzalintinib
Head and Neck Squamous Cell Carcinoma
August 2028Ongoing
GRFSGrifols S.A.
Phase 3Gamunex-C, 10% Injectable Solution
Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
August 2028Recruiting
IMVTImmunovant Inc.
Phase 2Imeroprubart
Chronic Inflammatory Demyelinating Polyneuropathy
August 2028Recruiting
JAZZJazz Pharmaceuticals plc
Phase 2/3JZP926 capsule
Juvenile Myoclonic Epilepsy
August 2028Recruiting
KODKodiak Sciences Inc
Phase 3Tabirafusp tedromer
Diabetic Macular Edema (DME)
August 2028Recruiting
MDGLMadrigal Pharmaceuticals Inc.
Phase 2Resmetirom
MASH - Metabolic Dysfunction-Associated Steatohepatitis
August 2028Recruiting
September 2028
BHVNBiohaven Ltd.
Phase 3BHV-1400
IgA Nephropathy
September 2028Not Yet Recruiting
CLDXCelldex Therapeutics Inc.
Phase 3barzolvolimab
Chronic Spontaneous Urticaria
September 2028Enrolling
GRFSGrifols S.A.
Phase 3Alpha-1 MP
Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
September 2028Enrolling
IBRXImmunityBio Inc.
Phase 3N-803
NSCLC Stage IV
September 2028Recruiting
NAMSNewAmsterdam Pharma Company N.V.
Phase 2Obicetrapib 10 mg
Preclinical Alzheimer's Disease
September 2028Recruiting
October 2028
JAZZJazz Pharmaceuticals plc
Phase 2JZP3507
Meningioma
October 2028Recruiting
NVCRNovoCure Limited
Phase 3NovoTTF-200T
Metastatic Non-small Cell Lung Cancer
October 2028Recruiting
ORKAOruka Therapeutics Inc.
Phase 2ORKA-002
Hidradenitis Suppurativa (HS)
October 2028Recruiting
UTHRUnited Therapeutics Corporation
Phase 1/210 GE Xenokidney
ESRD (End-Stage Renal Disease); Kidney Transplantation
October 2028Recruiting
VKTXViking Therapeutics Inc.
Phase 3VK2735 Oral
Weight Loss
October 2028Recruiting
November 2028
ALMSAlumis Inc.
Phase 3Open-Label Envudeucitinib
Plaque Psoriasis; Psoriasis (PsO)
November 2028Ongoing
BMRNBioMarin Pharmaceutical Inc.
Phase 1/2Dose 1 of BMN 331
Hereditary Angioedema; HAE
November 2028Ongoing
MRNAModerna Inc.
Phase 2mRNA-1982
Lyme Disease
November 2028Ongoing
December 2028
BHVNBiohaven Ltd.
Phase 2/3BHV-1300
Graves' Disease
December 2028Not Yet Recruiting
DNTHDianthus Therapeutics Inc.
Phase 3Claseprubart
Myasthenia Gravis, Generalized
December 2028Recruiting
DNTHDianthus Therapeutics Inc.
Phase 3Claseprubart
Chronic Inflammatory Demyelinating Polyneuropathy
December 2028Recruiting
ELVNEnliven Therapeutics Inc.
Phase 3ELVN-001
Chronic Myeloid Leukemia (CML); Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Pos
December 2028Not Yet Recruiting
INSMInsmed Incorporated
Phase 3Treprostinil Palmitil Inhalation Powder
Pulmonary Arterial Hypertension
December 2028Recruiting
INSMInsmed Incorporated
Phase 3Treprostinil Palmitil Inhalation Powder
Pulmonary Hypertension; Interstitial Lung Disease
December 2028Recruiting
KYMRKymera Therapeutics Inc.
Phase 2KT-621
Asthma (Diagnosis)
December 2028Recruiting
PHVSPharvaris N.V.
Phase 3Deucrictibant
Hereditary Angioedema (HAE)
December 2028Enrolling
RAREUltragenyx Pharmaceutical Inc.
Phase 1/2UX016
GNE Myopathy
December 2028Recruiting
TGTXTG Therapeutics Inc.
Phase 2Ublituximab
Schizophrenia
December 2028Recruiting
TLXTelix Pharmaceuticals Limited
Phase 2177Lu-TLX250
ccRCC; Renal Cell Carcinoma (Kidney Cancer)
December 2028Not Yet Recruiting
January 2029
MIRMMirum Pharmaceuticals Inc.
Phase 2Maralixibat
Intrahepatic Cholestasis of Pregnancy
January 2029Not Yet Recruiting
MRNAModerna Inc.
Phase 2mRNA-1195
Multiple Sclerosis
January 2029Recruiting
February 2029
ACADACADIA Pharmaceuticals Inc.
Phase 3ACP-204
Lewy Body Dementia Psychosis
February 2029Recruiting
March 2029
AGIOAgios Pharmaceuticals Inc.
Phase 3Mitapivat
Non-Transfusion-dependent Alpha-Thalassemia; Non-Transfusion-dependent Beta-Thalassemia
March 2029Recruiting
CELCCelcuity Inc.
Phase 3Arm A: Gedatolisib + Palbociclib + Fulvestrant
Breast Cancer
March 2029Recruiting
IONSIonis Pharmaceuticals Inc.
Phase 1/2ION582
Angelman Syndrome
March 2029Ongoing
PTCTPTC Therapeutics Inc.
Phase 3Vatiquinone
Friedreich's Ataxia
March 2029Not Yet Recruiting
RAREUltragenyx Pharmaceutical Inc.
Phase 2/3UX111
MPS IIIA; Sanfilippo Syndrome
March 2029Recruiting
RAREUltragenyx Pharmaceutical Inc.
Phase 1/2UX701
Wilson Disease
March 2029Ongoing
SYRESpyre Therapeutics Inc.
Phase 2SPY001
Ulcerative Colitis; Inflammatory Bowel Diseases
March 2029Enrolling
April 2029
ACADACADIA Pharmaceuticals Inc.
Phase 3ACP-204
Alzheimer's Disease Psychosis
April 2029Enrolling
NVCRNovoCure Limited
Phase 3Optune® device
Glioblastoma
April 2029Ongoing
May 2029
KYKOFKyowa Kirin Co. Ltd.
Phase 3KK8398
Achondroplasia
May 2029Ongoing
MIRMMirum Pharmaceuticals Inc.
Phase 2/3Brelovitug 300 mg
Chronic Hepatitis D Infection
May 2029Ongoing
RLAYRelay Therapeutics Inc.
Phase 1/2RLY-8161
Advanced NRAS-Mutant Melanoma; Advanced NRAS-Mutant Solid Tumors
May 2029Recruiting
June 2029
AGIOAgios Pharmaceuticals Inc.
Phase 3Mitapivat Matched Placebo
Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia
June 2029Recruiting
BMRNBioMarin Pharmaceutical Inc.
Phase 2/3BMN 333
Achondroplasia
June 2029Recruiting
EXELExelixis Inc.
Phase 2/3Zanzalintinib
Pancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET)
June 2029Recruiting
XENEXenon Pharmaceuticals Inc.
Phase 3Azetukalner
Bipolar Depression; Bipolar I Disorder
June 2029Ongoing
July 2029
CRNXCrinetics Pharmaceuticals Inc.
Phase 2atumelnant (CRN04894)
Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasia
July 2029Recruiting
DYNDyne Therapeutics Inc.
Phase 1/2DYNE-101
Myotonic Dystrophy Type 1 (DM1)
July 2029Ongoing
IDYAIDEAYA Biosciences Inc.
Phase 1/2IDE849
Small-cell Lung Cancer; Neuroendocrine Carcinomas
July 2029Recruiting
LQDALiquidia Corporation
Phase 3L606
Pulmonary Hypertension Due to Lung Disease (Disorder)
July 2029Recruiting
MDGLMadrigal Pharmaceuticals Inc.
Phase 2Resmetirom
MASH; MASH - Metabolic Dysfunction-Associated Steatohepatitis
July 2029Recruiting
ORKAOruka Therapeutics Inc.
Phase 2ORKA-002
Plaque Psoriasis
July 2029Enrolling
August 2029
AGIOAgios Pharmaceuticals Inc.
Phase 3Mitapivat Matched Placebo
Sickle Cell Disease
August 2029Recruiting
GRFSGrifols S.A.
Phase 3Xembify
Hypogammaglobulinemia; Bacterial Infections
August 2029Recruiting
IBRXImmunityBio Inc.
Phase 2N-803 + Pembrolizumab
Non-Small Cell Lung Cancer; Small Cell Lung Cancer
August 2029Ongoing
MRNAModerna Inc.
Phase 2mRNA-1283
SARS-CoV-2
August 2029Recruiting
September 2029
LNTHLantheus Holdings Inc.
Phase 2/3[68Ga]-LNTH-2401
Prostate Cancer
September 2029Recruiting
October 2029
NRIXNurix Therapeutics Inc.
Phase 3NX-5948
B-cell Lymphoma; Chronic Lymphocytic Leukemia
October 2029Recruiting
November 2029
COAGHemab Therapeutics Holdings Inc.
Phase 3Sutacimig
Thrombasthenia
November 2029Recruiting
UTHRUnited Therapeutics Corporation
Phase 1/2GGTA1 KO Thymokidney
ESRD (End-Stage Renal Disease); Kidney Transplantation
November 2029Recruiting
December 2029
CRSPCRISPR Therapeutics AG
Phase 1/2CTX112
Progressive Multiple Sclerosis (PMS); Neuromyelitis Optica
December 2029Not Yet Recruiting
UTHRUnited Therapeutics Corporation
Phase 3Inhaled Treprostinil
Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease
December 2029Enrolling
January 2030
CRSPCRISPR Therapeutics AG
Phase 1/2CTX112
B-cell Lymphoma; Non-Hodgkin Lymphoma
January 2030Recruiting
TGTXTG Therapeutics Inc.
Phase 2/3Ublituximab
Relapsing Multiple Sclerosis
January 2030Recruiting
March 2030
CRNXCrinetics Pharmaceuticals Inc.
Phase 2/3Atumelnant
Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasia
March 2030Recruiting
IMVTImmunovant Inc.
Phase 2IMVT-1402
Graves' Disease
March 2030Enrolling
April 2030
EXELExelixis Inc.
Phase 3Zanzalintinib
Colorectal Cancer
April 2030Recruiting
May 2030
EXELExelixis Inc.
Phase 3Cabozantinib
Cancer; Renal Cell Carcinoma (RCC)
May 2030Enrolling
ORKAOruka Therapeutics Inc.
Phase 2ORKA-001
Plaque Psoriasis
May 2030Recruiting
June 2030
CGONCG Oncology, Inc.
Phase 3Cretostimogene Grenadenorepvec
Non Muscle Invasive Bladder Cancer; High-grade Ta/ T1 Papillary Disease Bladder Cancer
June 2030Ongoing
CRSPCRISPR Therapeutics AG
Phase 1/2CTX460
Alpha-1 Antitrypsin Deficiency (AATD)
June 2030Recruiting
KYKOFKyowa Kirin Co. Ltd.
Phase 1/2KK8123
X-linked Hypophosphatemia
June 2030Recruiting
ZLABZai Lab Limited
Phase 3ZL-1310 in combination with Atezolizumab or Durvalumab
Extensive-Stage Small Cell Lung Cancer
June 2030Not Yet Recruiting
August 2030
AGIOAgios Pharmaceuticals Inc.
Phase 2/3AG-236
Polycythemia Vera
August 2030Not Yet Recruiting
HRMYHarmony Biosciences Holdings Inc.
Phase 3Pitolisant
Prader-Willi Syndrome
August 2030Enrolling
INSMInsmed Incorporated
Phase 3Treprostinil Palmitil Inhalation Powder
Progressive Pulmonary Fibrosis; Interstitial Lung Disease
August 2030Recruiting
TVTXTravere Therapeutics Inc.
Phase 3Pegtibatinase
Homocystinuria
August 2030Enrolling
October 2030
IDYAIDEAYA Biosciences Inc.
Phase 3Darovasertib
Uveal Melanoma
October 2030Recruiting
November 2030
RCUSArcus Biosciences Inc.
Phase 3Quemliclustat
Metastatic Pancreatic Ductal Adenocarcinoma
November 2030Ongoing
December 2030
DYNDyne Therapeutics Inc.
Phase 3Zeleciment Rostudirsen (DYNE-251)
Duchenne Muscular Dystrophy (DMD); Muscular Dystrophy, Duchenne
December 2030Recruiting
January 2031
INSMInsmed Incorporated
Phase 3Treprostinil Palmitil Inhalation Powder
Pulmonary Hypertension; Interstitial Lung Disease
January 2031Recruiting
February 2031
DNLIDenali Therapeutics Inc.
Phase 1/2tividenofusp alfa
Mucopolysaccharidosis II
February 2031Ongoing
EWTXEdgewise Therapeutics Inc.
Phase 2Sevasemten
Becker Muscular Dystrophy
February 2031Enrolling
PTCTPTC Therapeutics Inc.
Phase 3Sepiapterin
Phenylketonuria
February 2031Recruiting
May 2031
VERAVera Therapeutics Inc.
Phase 2Atacicept 150 mg
IgA Nephropathy (IgAN); Renal and Urinary Disorders
May 2031Enrolling
June 2031
BMRNBioMarin Pharmaceutical Inc.
Phase 3BMN 111
Achondroplasia
June 2031Ongoing
July 2031
RLAYRelay Therapeutics Inc.
Phase 2RLY-2608
PIK3CA-Related Overgrowth Spectrum (PROS); Lymphatic Malformations
July 2031Recruiting
September 2031
DYNDyne Therapeutics Inc.
Phase 1/2DYNE-251
Duchenne Muscular Dystrophy (DMD)
September 2031Ongoing
May 2032
TGTXTG Therapeutics Inc.
Phase 3Ublituximab
Relapsing Multiple Sclerosis (RMS)
May 2032Ongoing
July 2032
DNLIDenali Therapeutics Inc.
Phase 1/2DNL126
Mucopolysaccharidosis Type IIIA
July 2032Recruiting
April 2033
XENEXenon Pharmaceuticals Inc.
Phase 3XEN1101
Focal Epilepsy; Tonic-Clonic Seizures
April 2033Enrolling
May 2033
NRIXNurix Therapeutics Inc.
Phase 1/2NX-5948
B-cell Lymphoma; Chronic Lymphocytic Leukemia
May 2033Recruiting
December 2033
CRSPCRISPR Therapeutics AG
Phase 1/2CTX112
Warm Autoimmune Hemolytic Anemia (WAIHA); ITP - Immune Thrombocytopenia
December 2033Recruiting
March 2034
IDYAIDEAYA Biosciences Inc.
Phase 3Darovasertib
Uveal Melanoma
March 2034Recruiting
September 2034
UTHRUnited Therapeutics Corporation
Phase 2/3treprostinil SMI (treprostinil inhalation spray)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
September 2034Not Yet Recruiting
Want alerts instead of checking?

The full monitor adds notifications the moment a readout date arrives or a company files an 8-K, on your desktop and phone — plus per-company trial timelines across 107 biotechs.

Start free for 28 days or sign in →
Contact — questions, corrections, or a company you want added: dukeupt@gmail.com